{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.6","upperLimit":"22.7","value":"17.8"},{"groupId":"OG001","lowerLimit":"15.2","upperLimit":"24.7","value":"19.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"290"}],"units":"Participants"}],"description":"Disease-related symptom improvement rate by Week 12 was defined as the percentage of randomized participants who had a 10 point or greater decrease from baseline in average symptom burden index score at any time between randomization and Week 12. The participant portion of the Lung Cancer Symptom Scale (LCSS) consisted of 6 symptom-specific questions that addressed cough, dyspnea, fatigue, pain, hemoptysis, and anorexia, plus 3 summary items on symptom distress, interference with activity level, and global health-related Quality of Life (QoL). The scores range from 0 to 100, with 0 representing the best possible score and 100 being the worst possible score. The average symptom burden index score at each assessment was defined as the mean of the 6 symptom-specific questions of the LCSS. 95% CIs were computed using Clopper-Pearson Method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG001","title":"Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Randomization to Week 12","title":"Percentage of Participants Experiencing Disease-Related Symptom Improvement by Week 12","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}